Johnson & Johnson news

   Watch this stock
Showing stories 11 - 20 of about 119   

Articles published

JNJ 104.30 -2.29 (-2.15%)
price chart
Defective Surgical Product Lawsuits Filed Against Johnson & Johnson
PALM BEACH GARDENS, Fla., Sep 30, 2014 (BUSINESS WIRE) -- Johnson & Johnson has been accused of knowingly developing and marketing a defective medical device known as Prolene´┐Ż mesh used in hernia surgery in a series of lawsuits filed in New ...
Johnson & Johnson Should Ignore Those Breakup Calls
Still, there are plenty of investors calling for Johnson & Johnson to break itself up into smaller pieces, even though the company is posting 9% year-over-year revenue growth.
Johnson & Johnson: The One Stock You Should Ever Own? (JNJ)  Seeking Alpha (registration)
Short Interest in Johnson & Johnson Decreases By 13.2% (JNJ)  Mideast Time
Related articles »  
Johnson & Johnson to buy private drug developer for $1.75 billion
(Reuters) - Johnson & Johnson (JNJ.N) agreed to pay $1.75 billion (1.08 billion pounds) in cash to buy privately held Alios BioPharma Inc, which is developing a drug for a respiratory viral infection for which there is no approved treatment.
Interesting December Stock Options for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson JNJ -0.52% (NYSE: JNJ). So this week we highlight one interesting put contract, and one interesting call contract ...
Related articles »  
Achillion Pharmaceuticals, Inc. Less Attractive Amid Johnson & Johnson/Alios ...
Wells Fargo analyst Brian Abrahams notes that the Alios deal likely reduces interest in Achillion as a takeover target by Johnson & Johnson, citing similarities in the Alios and Achillion drug pipelines. Deutsche Bank analyst Alethia Young, however ...
Did Achillion Pharmaceuticals, Inc. Get Left Out in the M&A Cold?  Motley Fool
Related articles »  
Why Johnson & Johnson (JNJ) Stock Is Lower Today
"We rate JOHNSON & JOHNSON (JNJ) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate.
Sanford C. Bernstein Downgrades Johnson & Johnson to Market Perform (JNJ)  Watch List News (press release)
Sanford C. Bernstein Lowers Johnson & Johnson to Market Perform (JNJ)  sleekmoney
Related articles »  
Gas leak evacuates Johnson & Johnson, auto shop on Route 202 in Raritan
RARITAN BOROUGH - An active gas line leak has evacuated at least one building in the area of Johnson & Johnson NCS on Route 202, a fire official said.
Is It Time to Buy Johnson & Johnson's Stock?
A common belief among investors is that it can be considerably tougher for megacap blue-chip companies to double compared to small-caps stocks.
Related articles »  
The New #14 Most Shorted Dow Component: Johnson & Johnson
The most recent short interest data has been released by the NASDAQ for the 09/15/2014 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by ...
Related articles »  
Johnson & Johnson to buy private drug developer for $1.75 bln
BANGALORE: Johnson & Johnson said it would buy privately held drug developer Alios BioPharma Inc for $1.75 billion in cash, to access a portfolio of drugs targeting viral infections.